Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
L Tao, Y Zhou, Y Luo, J Qiu, Y **ao, J Zou… - MedComm …, 2024 - Wiley Online Library
Epigenetic regulation refers to the alteration of gene expression independent of changes in
DNA sequence. It involves chemical modifications such as DNA methylation, histone …
DNA sequence. It involves chemical modifications such as DNA methylation, histone …
Richter syndrome: Novel insights into the biology of transformation
EM Parry, E Ten Hacken, CJ Wu - Blood, The Journal of the …, 2023 - ashpublications.org
Although the genetic landscape of chronic lymphocytic leukemia (CLL) has been broadly
profiled by large-scale sequencing studies performed over the past decade, the molecular …
profiled by large-scale sequencing studies performed over the past decade, the molecular …
The multi-CDK inhibitor dinaciclib reverses bromo-and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin …
AR Marr, M Halpin, DL Corbin, Y Asemelash… - … Hematology & Oncology, 2024 - Springer
Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival
across a broad range of molecular subtypes. Development of efficacious and well-tolerable …
across a broad range of molecular subtypes. Development of efficacious and well-tolerable …
[HTML][HTML] DLBCL arising from indolent lymphomas: how are they different?
Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable,
clinical inflection point in the natural history of indolent lymphomas. Large retrospective …
clinical inflection point in the natural history of indolent lymphomas. Large retrospective …
PRMT5 as a potential therapeutic target in MYC-amplified medulloblastoma
Simple Summary Medulloblastoma is the most prevalent intracerebellar pediatric brain
tumor, accounting for approximately 20% of all childhood brain tumors and over 60% of …
tumor, accounting for approximately 20% of all childhood brain tumors and over 60% of …
Protein arginine methyltransferases (PRMTs): orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance
Y Gao, C Feng, J Ma, Q Yan - Biochemical pharmacology, 2024 - Elsevier
Abstract Protein Arginine Methyltransferases (PRMTs) are a family of enzymes regulating
protein arginine methylation, which is a post-translational modification crucial for various …
protein arginine methylation, which is a post-translational modification crucial for various …
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
ME Long, S Koirala, S Sloan, F Brown-Burke… - Blood …, 2024 - ashpublications.org
Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma, and patients
who relapse on targeted therapies have poor prognosis. Protein arginine methyltransferase …
who relapse on targeted therapies have poor prognosis. Protein arginine methyltransferase …
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
F Brown-Burke, I Hwang, S Sloan… - Blood …, 2023 - ashpublications.org
Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of
non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The …
non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The …
Arginine: at the crossroads of nitrogen metabolism
TS Fung, KW Ryu, CB Thompson - The EMBO Journal, 2025 - embopress.org
L-arginine is the most nitrogen-rich amino acid, acting as a key precursor for the synthesis of
nitrogen-containing metabolites and an essential intermediate in the clearance of excess …
nitrogen-containing metabolites and an essential intermediate in the clearance of excess …
Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing
MTS Bertilaccio, SS Chen - Frontiers in immunology, 2024 - frontiersin.org
Although the chronic lymphocytic leukemia (CLL) treatment landscape has changed
dramatically, unmet clinical needs are emerging, as CLL in many patients does not respond …
dramatically, unmet clinical needs are emerging, as CLL in many patients does not respond …